Apr 09, 2008 - Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced that preclinical data from its Toll-Like Receptor (TLR) programs will be presented at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) being held in San Diego, CA, April 12-16, 2008...... Abstract 2078 entitled "Antitumor activity of IMO-2055, an agonist of TLR9, in combination with erlotinib and bevacizumab in non-small cell lung cancer xenografts in mice" will be presented by Idera. In the study, IMO-2055, a TLR9 agonist, was evaluated in combination with erlotinib and bevacizumab in preclinical mice models... Idera Pharmaceuticals' Press Release -
